相对生物利用度

  • 网络Relative bioavailability;relativebioavailability;Frel
相对生物利用度相对生物利用度
  1. 结论盐酸伊曲康唑分散片的平均相对生物利用度为142.29%,较斯皮仁诺有明显提高(P<0.05),双单侧t检验的结果表明两制剂的lnAUC0-48和lnρmax均为生物不等效。

    CONCLUSION The mean relative bioavailability is 142.29 % . The AUC of the dispersible tablets are significantly higher than that of capsules ( P < 0.05 ) . The test and reference formulations are not bioequivalent .

  2. HPLC测定血清中β-胡萝卜素及其相对生物利用度研究

    β - carotene determined in serum by HPLC and its relative bioavailability

  3. 青霉素V钾健康人体药物动力学及相对生物利用度

    Study on the pharmacokinetics and relative bioavailability of penicillin V potassium in healthy volunteers

  4. HPLC测定对乙酰氨基酚鼻腔滴剂的人体相对生物利用度

    Relative bioavailability of acetaminophen nasal drops in human volunteers by reversed phase HPLC

  5. 辅酶Q(10)片药动学与人体相对生物利用度试验

    Studies on relative bioavailability and pharmacokinetics of coenzyme-Q _ ( 10 ) tablets

  6. 各药代动力学参数无显著性差异(P>0.05)。试验制剂氟康唑胶囊相对生物利用度F为(104.3±8.5)%。

    The relative bioavailability of the tested fluconazole was ( 104.3 ± 8.5 ) % .

  7. 试验制剂伊曲康唑分散片相对生物利用度F为100.53%±9.58%,双单侧t-检验和(1-2α)置信区间分析显示,两制剂为生物等效制剂。

    The t-test and ( 1-2 α) confidence interval analysis show that two preparations were bioequivalent .

  8. 目的:研究青霉素V钾颗粒剂在健康人体中的相对生物利用度,评价其生物等效性。

    Aim : To study the pharmacokinetics and relative bioavailability of penicillin ⅴ potassium in healthy volunteers .

  9. 结论:以A厂复方卡托普利片为标准算得B厂复方卡托普利片中卡托普利的相对生物利用度(F)为99.37%。

    CONCLUSIONS : The results showed that the bioavailability for the testing tablet was 99.37 % , the two formulations were bioequivalent .

  10. 维生素CNa胶囊与维生素C片剂的相对生物利用度比较

    Comparison of bioavailability between sodium Vitamin-C capsule and tablet in healthy subjects

  11. 受试药与参比药比较,相对生物利用度F为100.6±13.1%。

    Compared with reference formulation , the relative bioavailability ( F ) of test formulation was 100.6 ± 13.1 % .

  12. 目的:对国产盐酸氟西汀(Flu)胶囊进行相对生物利用度研究。

    AIM : To study the relative bioavailability of domestic fluoxetine hydrochloride ( Flu ) capsules .

  13. 目的建立HPLC法测定人血浆中头孢他美的浓度,并研究头孢他美酯分散片在人体内的相对生物利用度及生物等效性。

    OBJECTIVE To determine Cefetamet in human plasma by HPLC method , and study on its relative bioavailability and bioequivalence .

  14. 目的:研究po洛伐他汀胶囊与美降之片后,洛伐他汀在血浆中的药动学与相对生物利用度。

    OBJECTIVE : To study the pharmacokinetics and relative bioavailability of lovastatin capsule .

  15. A、B的相对生物利用度分别为(114.1±20.9)%、(114.8±9.0)%,三者具有生物等效性。

    The relative bioavailability of A and B were ( 114.1 ± 20.9 ) % and ( 114.8 ± 9.0 ) % , respectively . Three preparations were bioequivalent .

  16. 格列本脲二甲双胍片健康人体药动学和相对生物利用度研究二甲双胍格列本脲片中两种成分的离子对HPLC法测定

    Pharmacokinetics and Relative Bioavailability of Metformin-glibenclamide Release Tablets ; Determination of two components in metformin hydrochloride and glibenclamide tablets by ion-pair HPLC method

  17. 用HPLC法同时测定血浆中克拉维酸和阿莫西林的浓度,计算克拉维酸和阿莫西林的药代动力学参数,计算分散片的相对生物利用度。

    Bioequivalence of amoxicillin and clavulanic acid tablets in healthy volunteers The plasma concentration of clavulanic acid and amoxicillin simultaneous were determined with HPLC .

  18. 与姜黄素溶液相比,姜黄素PLGA纳米混悬液的相对生物利用度为1182.9%。

    Compared to curcumine solution , the relative bioavailability of Cur-PLGA-NPs was 1182.9 % .

  19. 经统计学分析表明,两者无显著性差异(P>0.05)。结论:贝氏萘普生片对联邦萘普生片的相对生物利用度为(102.72±13.76)%,两种萘普生片具有生物等效性。

    Conclusion : The relative bioavailability of NAPB tablets was ( 102.72 ± 13.76 ) % compared with NAPL tablets . The result of the statistical analysis showed that the two formations were bioequivalent .

  20. HPLC-MS测定人血浆中的依那普利及其人体药动学和相对生物利用度研究

    HPLC-MS Determined Enalapril in Human Plasma Its Pharmacokinetic and Relative Bioavailability

  21. 目的:研究po氨糖美辛肠溶片在20名健康志愿者体内的相对生物利用度和生物等效性。

    OBJECTIVE : To study the relative bioavailability and bioequivalence of glucosamine indometacin enteric-coated tablets in 20 healthy volunteers .

  22. 人血浆中氟康唑的HPLC-MS测定及其相对生物利用度

    Determination of Fluconazole and its Relative Bioavailability in Human Plasma by HPLC-MS

  23. 目的评价pH依赖型盐酸二甲双胍缓释微丸(T1)和非pH依赖型盐酸二甲双胍缓释微丸(T2)在健康人体内的药代动力学和相对生物利用度。

    Objective To investigate the pharmacokinetics and relative bioavailability of the pH-dependent ( T1 ) and non-pH-dependent ( T2 ) sustained-release metformin hydrochloride pellets .

  24. 用高效液相色谱法,测定健康男性志愿者8名,血清中2种头孢克罗胶囊(T药、R药)的药物浓度,进行相对生物利用度研究。

    Relative bioavailability of two products of cefaclor capsules ( referred to as T and R ) in sera of eight healthy male volunteers were determined by high performance liquid chromato-graphy .

  25. 改进了测定人血清中格列齐特(1)的HPLC方法;在10名健康志愿者体内,研究了两种国产1片剂的相对生物利用度。

    A reversed-phase HPLC method was developcd for determination of gliclazide in human serum to study the relative bioavailability of two brands of domestic tablets in10 healthy volunteers .

  26. 以HPLC方法测定人体内血药浓度,以普通制剂为对照,研究了盐酸昂丹司琼缓释微丸的家犬体内相对生物利用度和药代动力学。

    A reversed-phase HPLC method was established for determination of OND drug plasma concentration . Pharmacokinetics of ondansetron sustained-release capsule and conventional capsule was studied in three dogs .

  27. HPLC-MS法研究氯雷他定片人体相对生物利用度及药代动力学

    Study of Pharmacokinetics and Relative Bioavailability of Loratadine Tablets by HPLC - MS Method

  28. ml-1。受试制剂对参比制剂的相对生物利用度为(105.00±30.08)%。

    The relative bioavailability of omeprazole capsule was ( 105.00 ± 30.08 ) % .

  29. 国产MINO·HCl相对生物利用度97.75±22.43%。

    The relative bioavailability of domestic MINO . HC1 is 97.75 ± 22.43 % .

  30. ml-1。奥美拉唑肠溶胶囊的相对生物利用度为(111.1±58.1)%。

    The relative bioavailability of omeprazole enteric-coated capsules was ( 111.1 ± 58.1 ) % .